Heterogeneity of SSRI response

Harvard Review of Psychiatry

Volumn 4, Issue 4, 1996, Pages 215-217

  Salzman, Carl ^a  

^a MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

DEPRESSION; HUMAN; NEUROTOXICITY; PHARMACOLOGY; PRIORITY JOURNAL; SEDATION; SHORT SURVEY; SIDE EFFECT;

EID: 0029856132     PISSN: 10673229     EISSN: None     Source Type: Journal    
DOI: 10.3109/10673229609030546     Document Type: Short Survey

References (13)

1. De Wilde J, Spiers R, Mertens C, Bartholomé F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand 1993;87:141-5.
2. Brown WA, Harrison W. Are patients who are intolerant to one SSRI intolerant to another? Psychopharmacol Bull 1992;28:253-6.
3. Joffe RT, Levitt AJ, Sokolov ST, Young LT. Response to an open trial of a second SSRI in major depression. J Clin Psychiatry 1996;57:114-5.
4. Sacchetti E, Conte G, Guarneri L. Are SSRI antidepressants a clinically homogeneous class of compounds [Letter]. Lancet 1994;344:126-7.
5. Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cyto-chrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-5.
6. De Vane CL. Pharmacokinetics of the selective serotonin reuptake inhibitors. J Clin Psychiatry 1992;53(2 suppl):13-9.
7. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 1995;56:12-21.
8. Barros J, Asnis L. An interaction of sertraline and desipramine [Letter]. Am J Psychiatry 1993;150:1751.
9. Lydiard RB, Anton RF, Cunningham T. Interactions between sertraline and tricyclic antidepressants [Letter]. Am J Psychiatry 1993;150:1125-6.
10. Nemeroff CB, DeVane CL, Pollock BC. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-20.
11. Beasley CM Jr, Sayler ME, Weiss AM, Potvin JH. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol 1992;12:328-33.
12. Keck PE Jr, McElroy SL. Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 1992;54:127-9.
13. Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: preliminary data for sertraline versus fluoxetine. J Clin Psychiatry 1995;56:288-96.